A CLINICAL STUDY ON HEPATITIS B UNDER THE INFLUENCE OF VASADI KWATH
Anupam Srivastava*, Ajai Kumar Pandey, Narasimha Murthy and
Rajendra Prasad
ABSTRACT
Background: Hepatitis B is emerging as a challenging health problem
in the present era. It is caused by Hepatitis B virus and is emerged as
an important risk factor for liver cirrhosis and Hepatocellular
Carcinoma. The consequences associated with Hepatitis B are
increasing many folds in the affected individual. The treatment
modalities are still evolving in conventional system of medicine but
antiviral and nucleotide analogues therapies are emerged as promising
hope for its management. However, research scholars are inclined to
the other remedial resources due to adverse effects and side effects of
available modern drugs for its management. Aims: To evaluate the
clinical efficacy and safety of Vasadi Kwath in the cases of Hepatitis B
and to evaluate the impact of Vasadi Kwath on the viral load in the cases of Hepatitis B.
Materials and Methods: A total of 50 patients of Hepatitis B were registered; in which 40
patients turned up for full follow‑up and 10 patients were dropped out from the study.
Patients were randomly allocated into two groups; Group‑A was treated with capsule Liv 52
HB (2 cap twice a day) while Group‑B was treated with Vasadi Kwath (40 ml twice a day)
and assessment was done at monthly intervals in three consecutive follow ups. Results: The
selected trial drug has shown significant response on subjective and objective parameters along with significant reduction in Hepatitis B viral load. The patients treated with Vasadi Kwath; 66.7% patients have shown reduction of Hepatitis B viral load <20 IU/ML, while 45.5% were observed in patients treated with Liv-52 HB. Conclusion: The Trial drug Vasadi Kwath possess Chologogue, Choleretic, Laxative, Purgative, Antioxidant, Adaptogenic and Immunomodulatory properties along with antiviral effect.
Keywords: Hepatitis B, Kamala, Interferons, Jaundice, Ayurvedic drug, Antiviral drug.
[Full Text Article]